Literature DB >> 24394817

Counterpoint: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? No.

Gene L Colice1, Steven Idell2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24394817      PMCID： PMC3896319          DOI： 10.1378/chest.13-2356

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  20 in total

1.  Surgical decortication as the first-line treatment for pleural empyema.

Authors:  Jung Ar Shin; Yoon Soo Chang; Tae Hoon Kim; Seok Jin Haam; Hyung Jung Kim; Chul Min Ahn; Min Kwang Byun
Journal:  J Thorac Cardiovasc Surg       Date:  2012-08-25       Impact factor: 5.209

2.  A randomized trial of empyema therapy.

Authors:  M A Wait; S Sharma; J Hohn; A Dal Nogare
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

3.  Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus.

Authors:  G Simpson; D Roomes; M Heron
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

4.  Management of parapneumonic effusions.

Authors:  R W Light
Journal:  Arch Intern Med       Date:  1981-09

Review 5.  The diagnosis and management of empyema in children: a comprehensive review from the APSA Outcomes and Clinical Trials Committee.

Authors:  Saleem Islam; Casey M Calkins; Adam B Goldin; Catherine Chen; Cynthia D Downard; Eunice Y Huang; Laura Cassidy; Jacqueline Saito; Martin L Blakely; Shawn J Rangel; Marjorie J Arca; Fizan Abdullah; Shawn D St Peter
Journal:  J Pediatr Surg       Date:  2012-11       Impact factor: 2.545

Review 6.  Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas.

Authors:  S A Sahn
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 7.  Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas: a systematic review and meta-analysis.

Authors:  Surinder Janda; John Swiston
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

Review 8.  Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline.

Authors:  G L Colice; A Curtis; J Deslauriers; J Heffner; R Light; B Littenberg; S Sahn; R A Weinstein; R D Yusen
Journal:  Chest       Date:  2000-10       Impact factor: 9.410

9.  U.K. Controlled trial of intrapleural streptokinase for pleural infection.

Authors:  Nicholas A Maskell; Christopher W H Davies; Andrew J Nunn; Emma L Hedley; Fergus V Gleeson; Robert Miller; Rhian Gabe; Glyn L Rees; Timothy E A Peto; Mark A Woodhead; Donald J Lane; Janet H Darbyshire; Robert J O Davies
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

10.  Surgical management of pleural empyema in the very elderly.

Authors:  M Schweigert; N Solymosi; A Dubecz; M Beron; L Thumfart; D Oefner-Velano; H J Stein
Journal:  Ann R Coll Surg Engl       Date:  2012-07       Impact factor: 1.891
View more
  11 in total

1.  Rebuttal from Drs Colice and Idell.

Authors:  Gene L Colice; Steven Idell
Journal:  Chest       Date:  2014-01       Impact factor: 9.410

2.  Response.

Authors:  Gene L Colice; Steven Idell
Journal:  Chest       Date:  2014-09       Impact factor: 9.410

3.  Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali Azghani; Sophia Karandashova; Chris Schaefer; Kathleen Koenig; Kris Stewart-Evans; Paul J Declerck; Steven Idell; Andrey A Komissarov
Journal:  Am J Respir Cell Mol Biol       Date:  2015-04       Impact factor: 6.914

4.  Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali O Azghani; Sophia Karandashova; Chris Schaefer; Serge V Yarovoi; Paul J Declerck; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

5.  Inhibition of Glycogen Synthase Kinase 3β Blocks Mesomesenchymal Transition and Attenuates Streptococcus pneumonia-Mediated Pleural Injury in Mice.

Authors:  Jake Boren; Grant Shryock; Alexis Fergis; Ann Jeffers; Shuzi Owens; Wenyi Qin; Kathleen B Koenig; Yoshikazu Tsukasaki; Satoshi Komatsu; Mitsuo Ikebe; Steven Idell; Torry A Tucker
Journal:  Am J Pathol       Date:  2017-11       Impact factor: 4.307

6.  Modified single-port non-intubated video-assisted thoracoscopic decortication in high-risk parapneumonic empyema patients.

Authors:  Chen-Hao Hsiao; Ke-Cheng Chen; Jin-Shing Chen
Journal:  Surg Endosc       Date:  2016-08-12       Impact factor: 4.584

7.  Precision-guided, Personalized Intrapleural Fibrinolytic Therapy for Empyema and Complicated Parapneumonic Pleural Effusions: The Case for the Fibrinolytic Potential.

Authors:  Steven Idell; Galina Florova; Sreerama Shetty; Torry Tucker; Richard Idell; Kathy Koenig; Ali Azghani; Najib M Rahman; Andrey Komissarov
Journal:  Clin Pulm Med       Date:  2017-07

8.  Thoracoscopic management of early stages of empyema: is this the golden standard?

Authors:  Hany Hasan Elsayed; Ahmed Mostafa; Essam Fathy; Haytham S Diab; Ibrahim Mostafa Nofal; Osama Abbas AbdelHamid; Hatem Yazeed El-Bawab; Ahmed A ElNori
Journal:  J Vis Surg       Date:  2018-05-29

9.  Safety and Efficacy of Intrapleural Tissue Plasminogen Activator and DNase during Extended Use in Complicated Pleural Space Infections.

Authors:  Jason R McClune; Candice L Wilshire; Jed A Gorden; Brian E Louie; Alexander S Farviar; Michael J Stefanski; Eric Vallieres; Ralph W Aye; Christopher R Gilbert
Journal:  Can Respir J       Date:  2016-06-30       Impact factor: 2.409

10.  Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models.

Authors:  Andrey A Komissarov; Galina Florova; Ali O Azghani; Ann Buchanan; Jake Boren; Timothy Allen; Najib M Rahman; Kathleen Koenig; Mignote Chamiso; Sophia Karandashova; James Henry; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-24       Impact factor: 5.464
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.